Clinical Trials Logo

SCA38 clinical trials

View clinical trials related to SCA38.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03109626 Completed - SCA38 Clinical Trials

Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38

SCA38DHA
Start date: June 17, 2015
Phase: N/A
Study type: Interventional

The project will study a therapeutic approach in Spinocerebellar Ataxia (SCA38) by DHA replacement. SCA38 is caused by missense mutations in the ELOVL5 (Elongation of very long chain fatty acids protein 5) gene. Background/Rationale: ELOVL5 is a microsomal fatty acid elongase gene required for the synthesis of arachidonic acid and DHA. In brain, it shows a peculiar high expression in cerebellar Purkinje cells. The ELOVL5 products, such as DHA, are decreased in SCA38 patients serum and DHA administered as a dietary supplement has been shown to improve SARA scores, to ameliorate quality of life, and to increase brain cerebellar hypometabolism (FDG-PET) in two SCA38 patients. Experimental Plan: The investigators will perform a randomized placebo-controlled trial by DHA supplementation on ten SCA38 patients, followed by an open-label phase. Expected results: DHA supplementation should be able to improve symptoms in SCA38 and to improve cerebellar hypometabolism in these patients.